Intech Biopharm Corporation (TPEX:6461)
Taiwan
· Delayed Price · Currency is TWD 18.00
-0.05 (-0.28%)
Apr 29, 2026, 1:17 PM CST
Intech Biopharm Revenue
In the year 2025, Intech Biopharm had annual revenue of 107.53M TWD with 170.31% growth. Intech Biopharm had revenue of 4.82M in the quarter ending December 31, 2025, a decrease of -56.74%.
Revenue
107.53M
Revenue Growth
+170.31%
P/S Ratio
29.95
Revenue / Employee
n/a
Employees
90
Market Cap
3.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.53M | 67.75M | 170.31% |
| Dec 31, 2024 | 39.78M | 13.93M | 53.90% |
| Dec 31, 2023 | 25.85M | 2.20M | 9.30% |
| Dec 31, 2022 | 23.65M | -15.25M | -39.21% |
| Dec 31, 2021 | 38.90M | 17.79M | 84.30% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genovate Biotechnology | 492.41M |
| Shine-On BioMedical | 30.00M |
| SYN-TECH Chem. & Pharm. | 1.30B |
| BRIM Biotechnology | 5.49M |
| HeXun Biosciences | 293.23M |
| BioGend Therapeutics | 222.34M |
| Apex Biotechnology | 1.94B |
| Energenesis Biomedical CO.,LTD. | 7.67M |